5 resultados para cytotoxin-associated gene A
em Instituto Politécnico do Porto, Portugal
Resumo:
Major depressive disorder (MDD) is a highly prevalent disorder, which has been associated with an abnormal response of the hypothalamus–pituitary–adrenal (HPA) axis. Reports have argued that an abnormal HPA axis response can be due to an altered P-Glycoprotein (P-GP) function. This argument suggests that genetic polymorphisms in ABCB1 may have an effect on the HPA axis activity; however, it is still not clear if this influences the risk of MDD. Our study aims to evaluate the effect of ABCB1 C1236T, G2677TA and C3435T genetic polymorphisms on MDD risk in a subset of Portuguese patients. DNA samples from 80 MDD patients and 160 control subjects were genotyped using TaqMan SNP Genotyping assays. A significant protection for MDD males carrying the T allele was observed (C1236T: odds ratio (OR) = 0.360, 95% confidence interval [CI]: [0.140– 0.950], p = 0.022; C3435T: OR= 0.306, 95% CI: [0.096–0.980], p = 0.042; and G2677TA: OR= 0.300, 95% CI: [0.100– 0.870], p = 0.013). Male Portuguese individuals carrying the 1236T/2677T/3435T haplotype had nearly 70% less risk of developing MDD (OR = 0.313, 95% CI: [0.118–0.832], p = 0.016, FDR p = 0.032). No significant differences were observed regarding the overall subjects. Our results suggest that genetic variability of the ABCB1 is associated with MDD development in male Portuguese patients. To the best of our knowledge, this is the first report in Caucasian samples to analyze the effect of these ABCB1 genetic polymorphisms on MDD risk.
Resumo:
A obesidade e a diabetes mellitus tipo 2 (DM2) são considerados dois grandes problemas de saúde pública. A má alimentação e a falta de atividade física encontram-se entre os principais desencadeadores de um crescente número de indivíduos obesos, diabéticos e com sensibilidade à insulina diminuída. Este aumento tem motivado a comunidade científica a investigar cada vez mais para o elevado contributo da herança genética associada aos fatores sociais e nutricionais. O gene dos recetores ativados por proliferadores do peroxissoma gama 2 (PPARγ2) desempenha um papel importante no metabolismo lipídico. Uma vez que o PPARγ2 é maioritariamente expresso no tecido adiposo, uma redução moderada da sua atividade tem influência na sensibilidade à insulina, diabetes, e outros parâmetros metabólicos. Vários estudos sugerem que tanto fatores genéticos como fatores ambientais (tais como a dieta), poderão estar envolvidos na formação de padrões associados ao polimorfismo Pro12Ala com a composição corporal em diferentes populações humanas. Os diversos estudos genéticos envolvendo o estudo do polimorfismo Pro12Ala do PPARγ2 na suscetibilidade de possuir risco de diabetes e obesidade em várias populações têm proposto conclusões diversas. Em alguns parece haver mais associações do que outros e, às vezes, não demonstram sequer associação. Desta forma, o presente trabalho teve como objectivo contribuir para a elucidação do impacto do polimorfismo Pro12Ala do PPARγ2 na resistência à insulina associada à DM2 e na obesidade, mediante estudo sistematizado da literatura existente até à data, através de meta análise. Do total de uma pesquisa de 63 publicações, foram incluídos 32 artigos no presente estudo, sendo que destes 25 foram incluídos na síntese qualitativa e 11 incluídos na sintese quantitativa. No presente trabalho pode-se concluir que existe evidência estatística que suporta a hipótese de que o polimorfismo Pro12Ala do PPARγ2 pode ser considerado um fator protetor para a DM2 [p <0,05 e OR (odds ratio) 0,702, com IC (intervalos de confiança) com valores que nunca incluem o 1]. No entanto, e mediante os mesmos pressupostos, o mesmo polimorfismo pode ser considerado um fator de risco ao desenvolvimento de obesidade, pela evidência estatística [p <0,05 e OR de 1,196, com IC com valores que nunca incluem o 1].
Resumo:
O Factor Neurotrófico Derivado do Cérebro (BDNF) está associado a processos de crescimento, diferenciação e sobrevivência das células neuronais. A expressão diferencial do BDNF, particularmente no hipocampo, está relacionada com a manifestação clínica de algumas doenças do foro psiquiátrico e cognitivo como a doença de Huntington, Alzheimer, depressão e esquizofrenia. Este trabalho pretende dar conhecimento das técnicas utilizadas para avaliar a expressão do gene BDNF. As técnicas de ELISA, IHC e Western blot, por permitirem a avaliação precisa da expressão de BDNF, são úteis para uma melhor compreensão, diagnóstico e tratamento de algumas doenças neurodegenerativas.
Resumo:
Objective Deregulation of FAS/FASL system may lead to immune escape and influence bacillus Calmette-Guérin (BCG) immunotherapy outcome, which is currently the gold standard adjuvant treatment for high-risk non–muscle invasive bladder tumors. Among other events, functional promoter polymorphisms of FAS and FASL genes may alter their transcriptional activity. Therefore, we aim to evaluate the role of FAS and FASL polymorphisms in the context of BCG therapy, envisaging the validation of these biomarkers to predict response. Patients and methods DNA extracted from peripheral blood from 125 patients with bladder cancer treated with BCG therapy was analyzed by Polymerase Chain Reaction—Restriction Fragment Length Polymorphism for FAS-670 A/G and FASL-844 T/C polymorphisms. FASL mRNA expression was analyzed by real-time Polymerase Chain Reaction. Results Carriers of FASL-844 CC genotype present a decreased recurrence-free survival after BCG treatment when compared with FASL-844 T allele carriers (mean 71.5 vs. 97.8 months, P = 0.030) and have an increased risk of BCG treatment failure (Hazard Ratio = 1.922; 95% Confidence Interval: [1.064–3.471]; P = 0.030). Multivariate analysis shows that FASL-844 T/C and therapeutics scheme are independent predictive markers of recurrence after treatment. The evaluation of FASL gene mRNA levels demonstrated that patients carrying FASL-844 CC genotype had higher FASL expression in bladder tumors (P = 0.0027). Higher FASL levels were also associated with an increased risk of recurrence after BCG treatment (Hazard Ratio = 2.833; 95% Confidence Interval: [1.012–7.929]; P = 0.047). FAS-670 A/G polymorphism analysis did not reveal any association with BCG therapy outcome. Conclusions Our results suggest that analysis of FASL-844 T/C, but not FAS-670 A/G polymorphisms, may be used as a predictive marker of response to BCG immunotherapy.
Resumo:
Previous experiments revealed that DHH1, a RNA helicase involved in the regulation of mRNA stability and translation, complemented the phenotype of a Saccharomyces cerevisiae mutant affected in the expression of genes coding for monocarboxylic-acids transporters, JEN1 and ADY2 (Paiva S, Althoff S, Casal M, Leao C. FEMS Microbiol Lett, 1999, 170∶301–306). In wild type cells, JEN1 expression had been shown to be undetectable in the presence of glucose or formic acid, and induced in the presence of lactate. In this work, we show that JEN1 mRNA accumulates in a dhh1 mutant, when formic acid was used as sole carbon source. Dhh1 interacts with the decapping activator Dcp1 and with the deadenylase complex. This led to the hypothesis that JEN1 expression is post-transcriptionally regulated by Dhh1 in formic acid. Analyses of JEN1 mRNAs decay in wild-type and dhh1 mutant strains confirmed this hypothesis. In these conditions, the stabilized JEN1 mRNA was associated to polysomes but no Jen1 protein could be detected, either by measurable lactate carrier activity, Jen1-GFP fluorescence detection or western blots. These results revealed the complexity of the expression regulation of JEN1 in S. cerevisiae and evidenced the importance of DHH1 in this process. Additionally, microarray analyses of dhh1 mutant indicated that Dhh1 plays a large role in metabolic adaptation, suggesting that carbon source changes triggers a complex interplay between transcriptional and post-transcriptional effects.